Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ahlenstiel, Golo
STRIVE-4, NCT03855917: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir	Recruiting	4	30	RoW	Sofosbuvir 400mg [Sovaldi], Sovaldi, Glecaprevir/pibrentasvir (300mg/120mg), Maviret	Kirby Institute	Hepatitis C	02/26	02/26
CIRCUIT, NCT05415267: Immunosuppression and COVID-19 Boosters	Recruiting	3	320	RoW	diphtheria and tetanus toxoids (adsorbed) vaccine, ADT Booster, COVID-19 vaccine	Kirby Institute, Seqirus Pty Ltd, Australia, Medical Research Future Fund	COVID-19	12/26	12/26
ICEMELT, NCT04631731: Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity	Recruiting	1/2	200	RoW	Blood screening, Tissue screening	Western Sydney Local Health District, University of Western Sydney, Bristol-Myers Squibb	Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma, Gastric Cancer, Hepatocellular Carcinoma, Endometrial Cancer, Mesothelioma	12/24	12/25
NCT04595734: Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.	Recruiting	N/A	500	RoW	No intervention due to observational methods of study	Western Sydney Local Health District, University of Western Sydney	Lung Cancer Stage IV, Lung Cancer, Non-small Cell, Hepatitis	01/23	01/25
TOPIC, NCT03981211: Treatment of HOsPitalised Inpatients for Hepatitis C (): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs	Recruiting	N/A	60	RoW	Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet, Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet	Kirby Institute	Hepatitis C, Liver Inflammation, Liver Cirrhoses	02/25	02/25
NCT05042544: The National Australian HCV Point-of-Care Testing Program	Recruiting	N/A	40000	RoW	Point-of-Care Testing	Kirby Institute, Flinders University	Hepatitis C	12/24	12/26
REACH-B, NCT04914611: Real World Assessment of People Living With Chronic Hepatitis B in Australia	Recruiting	N/A	10000	RoW	No intervention	Kirby Institute	Hepatitis B	07/26	07/27